MK1026-010: A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib (MK-1026) Plus Venetoclax Versus Venetoclax Plus Rituximab in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Following at Least 1 Prior Therapy (BELLWAVE-010)

A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib (MK-1026) Plus Venetoclax Versus Venetoclax Plus Rituximab in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Following at Least 1 Prior Therapy (BELLWAVE-010)
Principal Investigator
Safi, Salah Ud Din
Phase
III
Age Group
Adult
Applicable Disease Sites
Leukemia
Lymphoma
Participating Institutions
Mary Babb Randolph Cancer Center
Contacts
Caitlin Slack, BS
Clinical Research Coordinator
Email:

View on ClinicalTrials.gov

Quick Search

Use the full search for additional searching options.